Author Interviews, Cancer Research, Dermatology, JAMA / 06.10.2025
Vanderbilt Study Analyzes Effect of Nicotinamide on Skin Cancer Prevention
MedicalResearch.com Interview with:
[caption id="attachment_70681" align="alignleft" width="167"]
Dr. Wheless[/caption]
Lee Wheless, MD, PhD
Assistant Professor
Department of Dermatology
Department of Medicine, Division of Epidemiology
Vanderbilt University Medical Center
Staff Physician
Tennessee Valley Health System VA Medical Center
MedicalResearch.com: What is the background for this study?
Response: Nicotinamide has been in use for skin cancer prevention for at least a decade. A more recent trial among solid organ transplant recipients (SOTR) specifically concluded that there was no benefit in this population. While that study had a number of issues, it really led dermatologists to question whether it was efficacious. This coupled with another study around the same time that suggested that metabolites of nicotinamide might increase the risk of major adverse cardiovascular events (MACE).
My group earlier this year conducted a similar study to this one showing that we really did not observe any increase in MACE at the population level. We then turned to address of the question of if nicotinamide was actually useful in reducing skin cancer risk.
Dr. Wheless[/caption]
Lee Wheless, MD, PhD
Assistant Professor
Department of Dermatology
Department of Medicine, Division of Epidemiology
Vanderbilt University Medical Center
Staff Physician
Tennessee Valley Health System VA Medical Center
MedicalResearch.com: What is the background for this study?
Response: Nicotinamide has been in use for skin cancer prevention for at least a decade. A more recent trial among solid organ transplant recipients (SOTR) specifically concluded that there was no benefit in this population. While that study had a number of issues, it really led dermatologists to question whether it was efficacious. This coupled with another study around the same time that suggested that metabolites of nicotinamide might increase the risk of major adverse cardiovascular events (MACE).
My group earlier this year conducted a similar study to this one showing that we really did not observe any increase in MACE at the population level. We then turned to address of the question of if nicotinamide was actually useful in reducing skin cancer risk.